abobotulinumtoxinA
Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Acebutolol
Mecamylamine may increase the hypotensive activities of Acebutolol.
Acemetacin
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Acemetacin.
Advertisement
Aclarubicin
Aclarubicin may increase the neuromuscular blocking activities of Mecamylamine.
Aclidinium
Mecamylamine may increase the anticholinergic activities of Aclidinium.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.
Advertisement
Alfentanil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Alfentanil.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Mecamylamine.
Aliskiren
Mecamylamine may increase the hypotensive activities of Aliskiren.
Advertisement
Alphaprodine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Alphaprodine.
Alprenolol
Mecamylamine may increase the hypotensive activities of Alprenolol.
Aluminum
The serum concentration of Mecamylamine can be increased when it is combined with Aluminium.
Aluminum Hydroxide
The serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The serum concentration of Mecamylamine can be increased when it is combined with Almasilate.
Ambenonium
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ambenonium.
Ambrisentan
Mecamylamine may increase the hypotensive activities of Ambrisentan.
Amifostine
Mecamylamine may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Mecamylamine may increase the hypotensive activities of Amifostine.
Amikacin
Amikacin may increase the neuromuscular blocking activities of Mecamylamine.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Mecamylamine.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Mecamylamine.
Amlodipine
Mecamylamine may increase the hypotensive activities of Amlodipine.
Ammonium Chloride
The serum concentration of Mecamylamine can be decreased when it is combined with Ammonium chloride.
Amobarbital
Amobarbital may increase the hypotensive activities of Mecamylamine.
Amphetamine
Amphetamine may increase the hypotensive activities of Mecamylamine.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Mecamylamine.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Mecamylamine.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Amyl Nitrite.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Mecamylamine.
Apraclonidine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Apraclonidine.
Arbekacin
Arbekacin may increase the neuromuscular blocking activities of Mecamylamine.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Mecamylamine.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mecamylamine.
Atenolol
Mecamylamine may increase the hypotensive activities of Atenolol.
Atracurium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Mecamylamine.
Avanafil
Avanafil may increase the antihypertensive activities of Mecamylamine.
Azilsartan
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.
Azosemide
The risk or severity of adverse effects can be increased when Azosemide is combined with Mecamylamine.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Mecamylamine.
Barbital
Barbital may increase the hypotensive activities of Mecamylamine.
Benactyzine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Benactyzine.
Benazepril
Mecamylamine may increase the hypotensive activities of Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.
Benzthiazide
The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Mecamylamine.
Bepridil
Mecamylamine may increase the hypotensive activities of Bepridil.
Betaxolol
Mecamylamine may increase the hypotensive activities of Betaxolol.
Bethanidine
Bethanidine may increase the hypotensive activities of Mecamylamine.
Bimatoprost
Mecamylamine may increase the hypotensive activities of Bimatoprost.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Mecamylamine.
Bismuth Subcitrate
The serum concentration of Mecamylamine can be increased when it is combined with Bismuth Subcitrate.
Bisoprolol
Mecamylamine may increase the hypotensive activities of Bisoprolol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Mecamylamine.
Bosentan
Bosentan may increase the hypotensive activities of Mecamylamine.
Botulinum Toxin Type A
Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Bretylium
Mecamylamine may increase the hypotensive activities of Bretylium.
Brimonidine
Brimonidine may increase the antihypertensive activities of Mecamylamine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Mecamylamine.
Bumetanide
The risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mecamylamine.
Bupranolol
Mecamylamine may increase the hypotensive activities of Bupranolol.
Buprenorphine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Butylscopolamine.
Cafedrine
Mecamylamine may increase the hypotensive activities of Cafedrine.
Calcium Carbonate
The serum concentration of Mecamylamine can be increased when it is combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The serum concentration of Mecamylamine can be increased when it is combined with Calcium Carbonate.
Canagliflozin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.
Candesartan
Mecamylamine may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Mecamylamine may increase the hypotensive activities of Candesartan cilexetil.
Capreomycin
Capreomycin may increase the neuromuscular blocking activities of Mecamylamine.
Captopril
Mecamylamine may increase the hypotensive activities of Captopril.
Carteolol
Mecamylamine may increase the hypotensive activities of Carteolol.
Carvedilol
Mecamylamine may increase the hypotensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.
Celiprolol
Mecamylamine may increase the hypotensive activities of Celiprolol.
Chlorothiazide
The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorphenoxamine.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mecamylamine.
Chlortetracycline
Chlortetracycline may increase the neuromuscular blocking activities of Mecamylamine.
Chlorthalidone
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.
Cicletanine
Mecamylamine may increase the hypotensive activities of Cicletanine.
Cilazapril
Mecamylamine may increase the hypotensive activities of Cilazapril.
Clevidipine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.
Clindamycin
Clindamycin may increase the neuromuscular blocking activities of Mecamylamine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Mecamylamine.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Mecamylamine.
Clonidine
Clonidine may increase the hypotensive activities of Mecamylamine.
Clopamide
The risk or severity of adverse effects can be increased when Clopamide is combined with Mecamylamine.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Mecamylamine.
Codeine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.
Colistimethate
Colistimethate may increase the neuromuscular blocking activities of Mecamylamine.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Mecamylamine.
Cryptenamine
Mecamylamine may increase the hypotensive activities of Cryptenamine.
Cyclopenthiazide
The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Mecamylamine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mecamylamine.
Cyclothiazide
The risk or severity of adverse effects can be increased when Cyclothiazide is combined with Mecamylamine.
Dapagliflozin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.
Darunavir
The risk or severity of adverse effects can be increased when Darunavir is combined with Mecamylamine.
Daunorubicin
Daunorubicin may increase the neuromuscular blocking activities of Mecamylamine.
Debrisoquin
Mecamylamine may increase the hypotensive activities of Debrisoquin.
Demecarium
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Demecarium.
Demeclocycline
Demeclocycline may increase the neuromuscular blocking activities of Mecamylamine.
Deserpidine
Mecamylamine may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Mecamylamine.
Desloratadine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Mecamylamine.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.
Dextromoramide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dezocine.
Diazoxide
The risk or severity of adverse effects can be increased when Diazoxide is combined with Mecamylamine.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Mecamylamine.
Dihydralazine
Mecamylamine may increase the hypotensive activities of Dihydralazine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.
Dihydrostreptomycin
Dihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.
Diltiazem
Mecamylamine may increase the hypotensive activities of Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.
Diphenoxylate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.
Dipyridamole
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.
Distigmine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Donepezil.
Dorzolamide
Mecamylamine may increase the hypotensive activities of Dorzolamide.
Doxazosin
Doxazosin may increase the hypotensive activities of Mecamylamine.
Doxorubicin
Doxorubicin may increase the neuromuscular blocking activities of Mecamylamine.
Doxorubicin Hydrochloride
Doxorubicin may increase the neuromuscular blocking activities of Mecamylamine.
Doxycycline
Doxycycline may increase the neuromuscular blocking activities of Mecamylamine.
Doxycycline Anhydrous
Doxycycline may increase the neuromuscular blocking activities of Mecamylamine.
Duloxetine
Mecamylamine may increase the orthostatic hypotensive activities of Duloxetine.
Echothiophate
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Edrophonium.
Eluxadoline
Mecamylamine may increase the constipating activities of Eluxadoline.
Empagliflozin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.
Enalapril
Mecamylamine may increase the hypotensive activities of Enalapril.
Enalaprilat
Mecamylamine may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Mecamylamine may increase the hypotensive activities of Enalaprilat.
Epirubicin
Epirubicin may increase the neuromuscular blocking activities of Mecamylamine.
Eplerenone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Eplerenone.
Epoprostenol
Mecamylamine may increase the hypotensive activities of Epoprostenol.
Eprosartan
Mecamylamine may increase the hypotensive activities of Eprosartan.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.
Ethacrynate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.
Ethylmorphine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.
Felodipine
Mecamylamine may increase the hypotensive activities of Felodipine.
Fenoldopam
Mecamylamine may increase the hypotensive activities of Fenoldopam.
Fentanyl
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.
Ferulic Acid
Mecamylamine may increase the hypotensive activities of Ferulic acid.
Fesoterodine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.
Fosinopril
Mecamylamine may increase the hypotensive activities of Fosinopril.
Framycetin
Framycetin may increase the neuromuscular blocking activities of Mecamylamine.
Furazolidone
Furazolidone may increase the hypotensive activities of Mecamylamine.
Furosemide
The risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.
Galantamine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mecamylamine.
Gentamicin
Gentamicin may increase the neuromuscular blocking activities of Mecamylamine.
Ginkgo biloba extract
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.
Glycopyrronium
Mecamylamine may increase the anticholinergic activities of Glycopyrronium.
Guanabenz
Mecamylamine may increase the hypotensive activities of Guanabenz.
Guanadrel
Mecamylamine may increase the hypotensive activities of Guanadrel.
Guanethidine
Mecamylamine may increase the hypotensive activities of Guanethidine.
Guanfacine
Mecamylamine may increase the hypotensive activities of Guanfacine.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Mecamylamine.
Heroin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Heroin.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Mecamylamine.
Homatropine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Mecamylamine.
Hydralazine
Mecamylamine may increase the hypotensive activities of Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.
Hydrocodone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.
Hydromorphone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.
Hydrotalcite
The serum concentration of Mecamylamine can be increased when it is combined with Hydrotalcite.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mecamylamine.
Idarubicin
Idarubicin may increase the neuromuscular blocking activities of Mecamylamine.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Mecamylamine.
Imidapril
Mecamylamine may increase the hypotensive activities of Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Mecamylamine.
incobotulinumtoxinA
Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.
Indoramin
Mecamylamine may increase the hypotensive activities of Indoramin.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.
Iproniazid
Iproniazid may increase the hypotensive activities of Mecamylamine.
Irbesartan
Mecamylamine may increase the hypotensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Mecamylamine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Mecamylamine.
Isoflurophate
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Isoxsuprine.
Isradipine
Mecamylamine may increase the hypotensive activities of Isradipine.
Kanamycin
Kanamycin may increase the neuromuscular blocking activities of Mecamylamine.
kanamycin A
Kanamycin may increase the neuromuscular blocking activities of Mecamylamine.
Ketanserin
Mecamylamine may increase the hypotensive activities of Ketanserin.
Labetalol
Mecamylamine may increase the hypotensive activities of Labetalol.
Lacidipine
Mecamylamine may increase the hypotensive activities of Lacidipine.
Latanoprost
Mecamylamine may increase the hypotensive activities of Latanoprost.
Lercanidipine
Mecamylamine may increase the hypotensive activities of Lercanidipine.
Levobunolol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Mecamylamine.
Levodopa
Mecamylamine may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Mecamylamine.
Lincomycin
Lincomycin may increase the neuromuscular blocking activities of Mecamylamine.
Lisinopril
Mecamylamine may increase the hypotensive activities of Lisinopril.
Lisinopril Anhydrous
Mecamylamine may increase the hypotensive activities of Lisinopril.
Lofexidine
Mecamylamine may increase the hypotensive activities of Lofexidine.
Losartan
Mecamylamine may increase the hypotensive activities of Losartan.
Macitentan
Mecamylamine may increase the hypotensive activities of Macitentan.
Mafenide
The risk or severity of adverse effects can be increased when Mafenide is combined with Mecamylamine.
Magaldrate
The serum concentration of Mecamylamine can be increased when it is combined with Magaldrate.
Magnesium Hydroxide
The serum concentration of Mecamylamine can be increased when it is combined with Magnesium hydroxide.
Magnesium Oxide
The serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.
Magnesium Trisilicate
The serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.
Malathion
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Malathion.
Manidipine
Mecamylamine may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.
Mefloquine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Mecamylamine.
Mepirodipine
Mecamylamine may increase the antihypertensive activities of Barnidipine.
Methadone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methantheline.
Methazolamide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methazolamide.
Methenamine
The serum concentration of Mecamylamine can be decreased when it is combined with Methenamine.
Methixene
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Metixene.
Methohexital
Methohexital may increase the hypotensive activities of Mecamylamine.
Methscopolamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Methylscopolamine bromide.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.
Methyldopa
Mecamylamine may increase the hypotensive activities of Methyldopa.
METHYLDOPA ANHYDROUS
Mecamylamine may increase the hypotensive activities of Methyldopa.
Methylene blue
Methylene blue may increase the hypotensive activities of Mecamylamine.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Mecamylamine.
Metipranolol
Mecamylamine may increase the hypotensive activities of Metipranolol.
Metoclopramide
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Metoclopramide.
Metolazone
The risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.
Metoprolol
Mecamylamine may increase the hypotensive activities of Metoprolol.
Metrizamide
Metrizamide may increase the neuromuscular blocking activities of Mecamylamine.
Metyrosine
Mecamylamine may increase the hypotensive activities of Metyrosine.
Mianserin
Mianserin may increase the anticholinergic activities of Mecamylamine.
Mibefradil
Mecamylamine may increase the hypotensive activities of Mibefradil.
Minaprine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.
Minocycline
Minocycline may increase the neuromuscular blocking activities of Mecamylamine.
Minoxidil
Minoxidil may increase the hypotensive activities of Mecamylamine.
Mirabegron
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.
Moclobemide
Moclobemide may increase the hypotensive activities of Mecamylamine.
Moexipril
Mecamylamine may increase the hypotensive activities of Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Mecamylamine.
Morphine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.
Moxonidine
Mecamylamine may increase the hypotensive activities of Moxonidine.
Nabilone
Mecamylamine may increase the tachycardic activities of Nabilone.
Nadolol
Mecamylamine may increase the hypotensive activities of Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.
Nebivolol
Mecamylamine may increase the hypotensive activities of Nebivolol.
Neomycin
Neomycin may increase the neuromuscular blocking activities of Mecamylamine.
Neostigmine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Neostigmine.
Nesiritide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nesiritide.
Netilmicin
Netilmicin may increase the neuromuscular blocking activities of Mecamylamine.
Nialamide
Nialamide may increase the hypotensive activities of Mecamylamine.
Nicardipine
Mecamylamine may increase the hypotensive activities of Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Mecamylamine.
Nifedipine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.
Nilvadipine
Mecamylamine may increase the hypotensive activities of Nilvadipine.
Nimodipine
Mecamylamine may increase the hypotensive activities of Nimodipine.
Nisoldipine
Mecamylamine may increase the hypotensive activities of Nisoldipine.
Nitrendipine
Mecamylamine may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mecamylamine.
Nitroglycerin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitroglycerin.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Mecamylamine.
Normethadone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.
Obinutuzumab
Mecamylamine may increase the hypotensive activities of Obinutuzumab.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mecamylamine.
Octylonium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Otilonium.
Olmesartan
Mecamylamine may increase the hypotensive activities of Olmesartan.
onabotulinumtoxinA
Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Opium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.
Oxitropium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxitropium.
Oxprenolol
Mecamylamine may increase the hypotensive activities of Oxprenolol.
Oxybutynin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mecamylamine.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mecamylamine.
Pancuronium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.
Papaverine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.
Paregoric
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.
Pargyline
Pargyline may increase the hypotensive activities of Mecamylamine.
Paromomycin
Paromomycin may increase the neuromuscular blocking activities of Mecamylamine.
Penbutolol
Mecamylamine may increase the hypotensive activities of Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Mecamylamine.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Mecamylamine.
Perindopril
Mecamylamine may increase the hypotensive activities of Perindopril.
Phenelzine
Phenelzine may increase the hypotensive activities of Mecamylamine.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Mecamylamine.
Phenoxybenzamine
Mecamylamine may increase the hypotensive activities of Phenoxybenzamine.
Phentolamine
Mecamylamine may increase the hypotensive activities of Phentolamine.
Phentolamine Mesylate
Mecamylamine may increase the hypotensive activities of Phentolamine.
Physostigmine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.
Pinacidil
Mecamylamine may increase the hypotensive activities of Pinacidil.
Pindolol
Mecamylamine may increase the hypotensive activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Mecamylamine.
Pipazethate
The risk or severity of adverse effects can be increased when Pipazethate is combined with Mecamylamine.
Pipecuronium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.
Pirarubicin
Pirarubicin may increase the neuromuscular blocking activities of Mecamylamine.
Pirenzepine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.
Pirinitramide
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Piritramide.
Plicamycin
Plicamycin may increase the neuromuscular blocking activities of Mecamylamine.
Polymyxin B
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Mecamylamine.
Polymyxin B Sulfate
Polymyxin B Sulfate may increase the neuromuscular blocking activities of Mecamylamine.
Polythiazide
The risk or severity of adverse effects can be increased when Polythiazide is combined with Mecamylamine.
Potassium Chloride
Mecamylamine may increase the ulcerogenic activities of Potassium Chloride.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Mecamylamine.
Pramlintide
Pramlintide may increase the anticholinergic activities of Mecamylamine.
Prazosin
Prazosin may increase the hypotensive activities of Mecamylamine.
Primidone
Primidone may increase the hypotensive activities of Mecamylamine.
Probenecid
The risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine.
Procarbazine
Procarbazine may increase the hypotensive activities of Mecamylamine.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Mecamylamine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Mecamylamine.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Mecamylamine.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Mecamylamine.
Propiverine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Propiverine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Mecamylamine.
Propoxyphene
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.
Propranolol
Mecamylamine may increase the hypotensive activities of Propranolol.
Pyridostigmine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine.
Quetiapine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.
Quinapril
Mecamylamine may increase the hypotensive activities of Quinapril.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.
Quinidine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.
Quinine
Quinine may increase the hypotensive activities of Mecamylamine.
Ramipril
Mecamylamine may increase the hypotensive activities of Ramipril.
Rasagiline
Rasagiline may increase the hypotensive activities of Mecamylamine.
Remifentanil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.
Rescinnamine
Mecamylamine may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Mecamylamine.
Rilmenidine
Mecamylamine may increase the hypotensive activities of Rilmenidine.
rimabotulinumtoxinB
Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.
Riociguat
Mecamylamine may increase the hypotensive activities of Riociguat.
Risperidone
Mecamylamine may increase the hypotensive activities of Risperidone.
Rituximab
Mecamylamine may increase the hypotensive activities of Rituximab.
Rivastigmine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Rivastigmine.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Mecamylamine.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Mecamylamine.
Rosuvastatin
The risk or severity of adverse effects can be increased when Rosuvastatin is combined with Mecamylamine.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Mecamylamine.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Mecamylamine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Mecamylamine.
Secobarbital
Secobarbital may increase the hypotensive activities of Mecamylamine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.
Selegiline
Selegiline may increase the hypotensive activities of Mecamylamine.
Selexipag
Mecamylamine may increase the hypotensive activities of Selexipag.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Mecamylamine.
Sildenafil
The risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.
Silver Sulfadiazine
The risk or severity of adverse effects can be increased when Silver sulfadiazine is combined with Mecamylamine.
Simeprevir
The risk or severity of adverse effects can be increased when Simeprevir is combined with Mecamylamine.
Sisomicin
Sisomicin may increase the neuromuscular blocking activities of Mecamylamine.
Sodium Bicarbonate
The serum concentration of Mecamylamine can be increased when it is combined with Sodium bicarbonate.
Solifenacin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Solifenacin.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.
Spectinomycin
Spectinomycin may increase the neuromuscular blocking activities of Mecamylamine.
Spirapril
Mecamylamine may increase the hypotensive activities of Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.
Streptomycin
Streptomycin may increase the neuromuscular blocking activities of Mecamylamine.
Streptozocin
Streptozocin may increase the neuromuscular blocking activities of Mecamylamine.
Sufentanil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.
Sulfacetamide
The risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine.
Sulfacytine
The risk or severity of adverse effects can be increased when Sulfacytine is combined with Mecamylamine.
Sulfadiazine
The risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine.
Sulfadimethoxine
The risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Mecamylamine.
Sulfadoxine
The risk or severity of adverse effects can be increased when Sulfadoxine is combined with Mecamylamine.
Sulfalene
The risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Mecamylamine.
Sulfamerazine
The risk or severity of adverse effects can be increased when Sulfamerazine is combined with Mecamylamine.
Sulfamethazine
The risk or severity of adverse effects can be increased when Sulfamethazine is combined with Mecamylamine.
Sulfamethizole
The risk or severity of adverse effects can be increased when Sulfamethizole is combined with Mecamylamine.
Sulfamethoxazole
The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.
Sulfamoxole
The risk or severity of adverse effects can be increased when Sulfamoxole is combined with Mecamylamine.
Sulfanilamide
The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine.
Sulfapyridine
The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.
Sulfathiazole
The risk or severity of adverse effects can be increased when Sulfathiazole is combined with Mecamylamine.
Sulfisoxazole
The risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.
Sulpiride
Mecamylamine may increase the anticholinergic activities of Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine.
Tacrine
The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tacrine.
Tadalafil
Tadalafil may increase the antihypertensive activities of Mecamylamine.
Talinolol
Mecamylamine may increase the hypotensive activities of Talinolol.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Mecamylamine.
Tapentadol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.
Telmisartan
Mecamylamine may increase the hypotensive activities of Telmisartan.
Terazosin
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.
Terlipressin
Mecamylamine may increase the hypotensive activities of Terlipressin.
Tetrahydrocannabinol
Mecamylamine may increase the tachycardic activities of Dronabinol.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Mecamylamine.
Theodrenaline
Mecamylamine may increase the hypotensive activities of Theodrenaline.
Thiamylal
Thiamylal may increase the hypotensive activities of Mecamylamine.
Thiopental
Thiopental may increase the hypotensive activities of Mecamylamine.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Mecamylamine.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Mecamylamine.
Tibolone
Mecamylamine may increase the hypotensive activities of Tibolone.
Timolol
Mecamylamine may increase the hypotensive activities of Timolol.
Timolol Anhydrous
Mecamylamine may increase the hypotensive activities of Timolol.
Tiotropium
Mecamylamine may increase the anticholinergic activities of Tiotropium.
Tizanidine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.
Tobramycin
Tobramycin may increase the neuromuscular blocking activities of Mecamylamine.
Tolazoline
Mecamylamine may increase the hypotensive activities of Tolazoline.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Mecamylamine.
Toloxatone
Toloxatone may increase the hypotensive activities of Mecamylamine.
Tolterodine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolterodine.
Topiramate
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate.
Torsemide
Mecamylamine may increase the hypotensive activities of Torasemide.
Tramadol
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.
Trandolapril
Mecamylamine may increase the hypotensive activities of Trandolapril.
Tranylcypromine
Tranylcypromine may increase the hypotensive activities of Mecamylamine.
Travoprost
Mecamylamine may increase the hypotensive activities of Travoprost.
Treprostinil
Mecamylamine may increase the hypotensive activities of Treprostinil.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Mecamylamine.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.
Trichlormethiazide
The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.
Trimethaphan
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Trimethaphan.
Tromethamine
The serum concentration of Mecamylamine can be increased when it is combined with Tromethamine.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Mecamylamine.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Mecamylamine.
Tubocurarine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.
Umeclidinium
Mecamylamine may increase the anticholinergic activities of Umeclidinium.
UNOPROSTONE
Mecamylamine may increase the hypotensive activities of Unoprostone.
Urapidil
Mecamylamine may increase the hypotensive activities of Urapidil.
Valrubicin
Valrubicin may increase the neuromuscular blocking activities of Mecamylamine.
Valsartan
Mecamylamine may increase the hypotensive activities of Valsartan.
Vardenafil
Vardenafil may increase the antihypertensive activities of Mecamylamine.
Vecuronium
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.
Verapamil
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.
Vincamine
Mecamylamine may increase the hypotensive activities of Vincamine.
Vinpocetine
Mecamylamine may increase the hypotensive activities of Vinpocetine.
Xylometazoline
Mecamylamine may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Mecamylamine.
Zofenopril
Mecamylamine may increase the hypotensive activities of Zofenopril.
